MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals ... in a validated animal model of diabetic neuropathy. In the study, Type 2 diabetes was induced in rats using a high ...

Mira, eyes scrunched tight, tiny head on Wu’s shoulder, slept through it all. Her approach has taken that well-worn political cliche — politician kisses baby — and flipped it on its head.

(NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced compelling data demonstrating ...

Itzchak Angel, Chief Scientific Advisor at MIRA. "Seeing such robust responses in a validated model of diabetic neuropathy reinforces the potential clinical impact of Ketamir-2 and helps guide the ...

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals ...

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, ...

"Backstage has given me access to casting calls across the US while also giving me an opportunity to showcase a full portfolio of my skills and assets. Wonderful one-stop-shop." ...